Antitumour Activity of Patritumab Deruxtecan in Heavily Pretreated Patients with Active Brain Metastases of Breast Cancer and NSCLC By Ogkologos - October 29, 2025 45 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the cohorts 1 and 2 of the TUXEDO-3 study Source RELATED ARTICLESMORE FROM AUTHOR Rucaparib Monotherapy Provides Significant and Durable Long-Term Benefit as First-Line Maintenance for Patients with Advanced Ovarian Cancer with and without HRD FDA Approves Belantamab Mafodotin-blmf for Relapsed or Refractory Multiple Myeloma Long-Term Follow-Up Data Support Longer RFS with Adjuvant Nivolumab Than with Ipilimumab in Patients with Melanoma at High Risk for Recurrence MOST POPULAR Workout Wednesday – Back Stretches Part 2 July 29, 2020 Sacituzumab Govitecan Approved for Metastatic Triple-Negative Breast Cancer May 28, 2020 FDA Approves Ribociclib with an Aromatase Inhibitor and Ribociclib and Letrozole... October 28, 2024 Why People With Cancer Need to Be Taking Care of Their... August 27, 2020 Load more HOT NEWS When Ellen Found Out There Was A Grieving Mother In The... FLT3 Internal Tandem Duplication Measurable Residual Disease in Complete Remission Identifies... Learning to Advocate for Yourself – An Important Skill! An Abnormal Baseline Geriatric 8 Screening Tool Score Strongly Associates with...
